All Posts
How to Transition an AAV Gene Therapy Program from Adherent to Suspension Culture Safely
Transitioning an AAV gene therapy program from adherent cell culture to a suspension platform is
May 28, 2026
Transitioning an AAV gene therapy program from adherent cell culture to a suspension platform is
Grant Writing · Pharma & Drug Development · Complete Guide The Complete Guide
When a pharmaceutical or life sciences company receives a Form 483, Warning Letter, or Consent
Pharmacovigilance consulting has become a cornerstone of modern drug development and post-market surveillance. As regulatory
BOSTON, MA — May 6, 2026 — DES Pharma, a premier provider of strategic advisory
The countdown has officially begun. From May 11–14, 2026, the global biopharmaceutical community will descend
Biotech is the rare industry where a single decision — a missed FDA meeting, a
The pharmaceutical landscape is evolving rapidly, and staying ahead of the curve means keeping a
The Critical Bridge in Drug Development Technology transfer stands as one of the most pivotal—yet
Good Manufacturing Practice (GMP) is the lifeblood of the pharmaceutical industry. It is the minimum
Start building reliable, high-quality drug development programs today.